ATAI Life Sciences NV 9VC-DE:XETRA

*Data is delayed | Exchange | EUR
Last | 05/03/24 CEST
1.94quote price arrow down-0.03 (-1.60%)
Volume
3,500
52 week range
0.96 - 2.47
Loading...
  • Open2.00
  • Day High2.00
  • Day Low1.94
  • Prev Close1.97
  • 52 Week High2.47
  • 52 Week High Date04/08/24
  • 52 Week Low0.96
  • 52 Week Low Date12/01/23

Key Stats

  • Market Cap320.43M
  • Shares Out166.03M
  • 10 Day Average Volume1,982.56
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change39.68

KEY STATS

  • Open2.00
  • Day High2.00
  • Day Low1.94
  • Prev Close1.97
  • 52 Week High2.47
  • 52 Week High Date04/08/24
  • 52 Week Low0.96
  • 52 Week Low Date12/01/23
  • Market Cap320.43M
  • Shares Out166.03M
  • 10 Day Average Volume1,982.56
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change39.68

RATIOS/PROFITABILITY

  • EPS (TTM)-0.26
  • P/E (TTM)-7.45
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On ATAI Life Sciences NV

 

Profile

MORE
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002...
Florian Brand
Chief Executive Officer, Co-Founder
Anne Johnson
Chief Financial Officer
Address
Wallstrasse 16
Berlin
10179
Germany